Replies to post #9376 on Momenta Pharmaceuticals, Inc. (MNTA)

[floblu14]

Is there anything known about how they intend to differentiate this IVIG?

Bank of America Merrill Lynch 2012 Health Care Conference (Transcript) - May 16, 2012

Rick Shea -

....it’s been dubbed the Sialic Switch technology and it's based on a principle of activating an anti-inflammatory pathway by sialylating the Fc-linked glycans of antibodies. And this technology has the potential to increase the potency of these products and in the case of IVIG, which is our first product that would be applying this technology to and has the potential tool to reduce the dose which could provide for a significantly enhanced benefit for patients and also for supply chain.

So this is one area that would be applying this technology because of the platform that can be applied broadly to many different types of antibodies.

http://seekingalpha.com/article/601711-momenta-pharmaceuticals-management-presents-at-bank-of-america-merrill-lynch-2012-health-care-conference-transcript?page=3

[DewDiligence]

US IVIG market gets a new player (Biotest AG):

http://finance.yahoo.com/news/fda-approves-biotests-bivigam-intravenous-163000163.html

Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration.

…The U.S. IVIG market is the largest in the world and Biotest's entry into this market fulfills the company's longstanding vision of being a significant global participant. Biotest formed BPC as a U.S. subsidiary in 2007, with the purchase of Nabi Biopharmaceuticals' biologics strategic business unit, which included a plasma protein plant and plasma collection centers.